Article Information
History
- January 27, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Xuping Xie1,*,
- Yang Liu1,*,
- Jianying Liu2,3,*,
- Xianwen Zhang1,
- Jing Zou1,
- Camila R. Fontes-Garfias1,
- Hongjie Xia1,
- Kena A. Swanson4,
- Mark Cutler4,
- David Cooper4,
- Vineet D. Menachery2,3,
- Scott Weaver2,3,
- Philip R. Dormitzer4,# and
- Pei-Yong Shi1,3,5,6,7,#
- 1Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, U.S.A.
- 2Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, U.S.A.
- 3Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX, U.S.A.
- 4Pfizer, 401 N Middletown Rd., Pearl River, NY 10960, U.S.A.
- 5Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, U.S.A.
- 6Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, U.S.A.
- 7Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, U.S.A.
- ↵#Correspondence: P.R.D. (Philip.Dormitzer{at}pfizer.com) or P.-Y.S. (peshi{at}UTMB.edu)
↵* X.X., Y.L., and J.L. contributed equally to this study.
Posted January 27, 2021.
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera
